艾司西酞普兰所致QTc间期延长的研究进展  

The Advance of Escitalopram’s Drug-induced QTc Prolongation

作　　者：陈子木 袁勇贵[1] 徐治[1] CHEN Zi-mu;YUAN Yong-gui;XU Zhi(Department of Psychiatry,Zhongda Hospital of Southeast University,Nanjing 210000,China)

机构地区：[1]东南大学附属中大医院心理精神科

出　　处：《中国药学杂志》2019年第24期2043-2046,共4页Chinese Pharmaceutical Journal

摘　　要：艾司西酞普兰作为一种选择性5-羟色胺再摄取抑制剂,用于治疗抑郁症和焦虑症。近10年来研究表明,艾司西酞普兰可能导致QTc间期延长,诱发心律失常,增加尖端扭转型室速的风险,严重者导致心源性猝死。笔者以"escitalopram/citalopram""QT prolongation"为关键词,在Pub Med上检索近10年涉及艾司西酞普兰延长QTc间期相关文章。总结艾司西酞普兰致QTc间期延长的相关机制、危险因素等。Escitalopram,a selective serotonin re-uptake inhibitor( SSRI) antidepressant which is the( S)-enantiomer of citalopram,is worldwide used for the treatment of depressive and anxious disorders in clinical practice,however,recent data have indicated that high therapeutic escitalopram doses may cause the potential of QTc prolongation effect,which is a predisposing factor for arrhythmia. Nevertheless,in March 2012,the Food and Drug Administration( FDA) issued a safety bulletin advising the daily dosage of escitalopram should be restricted to a maximum of 20 mg daily in healthy adults and 10 mg maximum in high risk patients( eg > 60 years of age). In this review,we aimed to investigate what factors can affect and how escitalopram gives rise to QTc prolongation.

关 键 词：艾司西酞普兰 QTC间期延长 危险因素 HERG通道 腺苷A1受体 

分 类 号：R971[医药卫生—药品]